11 hours ago
HomeMarket NewsDr Lal PathLabs Q4 results beat estimates, declares ₹6 final dividend
Shares of Dr Lal PathLabs were trading 5.3% higher at ₹2934.25 on the BSE after the results were announced.
By Poonam Behura April 25, 2025, 3:03:25 PM IST (Published)
Indian diagnostic services provider Dr Lal PathLabs reported an 83.4% year-on-year (YoY) surge in fourth-quarter net profit on Friday, surpassing analyst expectations, driven by higher diagnostic volumes and improved operational efficiency.
Consolidated net profit for the quarter ended March 31 rose to ₹155 crore ($18.6 million) from ₹85 crore a year earlier, beating a CNBC-TV18 poll estimate of ₹100 crore.
Revenue from operations grew 10.5% YoY to ₹602.6 crore, aligning closely with the CNBC-TV18 poll forecast of ₹602 crore. Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased 16.8% to ₹169 crore, topping the poll estimate of ₹158 crore. The EBITDA margin expanded to 28% from 26.5% a year ago, compared with the expected 26.3%.
The company, which operates 280 labs across India, has been expanding its footprint in Tier-III and Tier-IV towns, contributing to robust volume growth. Dr Lal PathLabs also declared a fourth interim dividend of ₹6 per share for fiscal year 2025.
Shares of Dr Lal PathLabs were trading 5.3% higher at ₹2934.25 on the BSE after the results were announced.
